New drug combination for advanced liver cancer after standard treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for liver cancer that has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have liver cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer must have gotten worse or come back after at least one standard treatment.
- You need to be generally active – able to do light work or be fully active.
- Your liver and other organs must be working well enough, as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (JDB153 and serplulimab) for people with advanced pancreatic cancer that has progressed after standard treatments. The goal is to see if this combo can shrink tumors or slow the cancer's growth, and to check its safety.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two medicines (adebrelimab and apatinib) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combo can slow down the cancer and improve outcomes.
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of immunotherapy drugs (JS207 and JS007) against the current standard treatment (toripalimab plus bevacizumab) for advanced liver cancer that hasn't been treated before. The goal is to see if the new combo works better and shrinks tumors or delays growth.
Hear when a new Refractory Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.